AZTR

Azitra, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing advanced therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. It has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen its library of strains for drug-like molecules. Its lead product, ATR-12, is a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton syndrome, a chronic and fatal disease of the skin. Its advanced product, ATR-04, is a genetically modified strain of S. epidermidis for treating papulopustular rash. Its product ATR-01 is a human filaggrin protein for treating ichthyosis vulgaris, a chronic, xerotic (abnormally dry), and scaly skin disease.

Wall Street analysts forecast AZTR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AZTR is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Azitra Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Azitra Inc. EPS for the last quarter amounts to -0.67 USD, decreased -42.24 % YoY.

Azitra Inc (AZTR) has 12 emplpoyees as of December 15 2025.

Today AZTR has the market capitalization of 3.52M USD.